Importance of genetic polymorphisms in the response to age-related macular degeneration treatment

Importância dos polimorfismos genéticos na resposta terapêutica da degeneração macular relacionada à idade

ARTIGO DE REVISÃO

Importance of genetic polymorphisms in the response to age-related macular degeneration treatment

Importância dos polimorfismos genéticos na resposta terapêutica da degeneração macular relacionada à idade

Carlos Eduardo dos Reis Veloso^I; Luciana Negrão Frota de Almeida^I; Luiz Armando De Marco^II; Raul Nunes Galvarro Vianna^III; Márcio Bittar Nehemy^IV

^IPós-graduando (Doutorado), Departamento de Oftalmologia, Faculdade de Medicina, Universidade Federal de Minas Gerais – UFMG – Belo Horizonte (MG), Brasil

^IIUniversidade Federal de Minas Gerais (UFMG) – Belo Horizonte (MG), Brasil

^IIIUniversidade Federal Fluminense (UFF) – Rio de Janeiro (RJ), Brasil

^IVUniversidade Federal de Minas Gerais -UFMG – Belo Horizonte (MG), Brasil

^{Endereço para correspondência}

ABSTRACT

Age-related macular degeneration (AMD) is a degenerative disorder that affects the central retina and involves the Bruch's membrane, the retinal pigment epithelium and the photoreceptors. Recent studies have shown that polymorphisms of the CFH, LOC387715 and VEGF genes are associated with AMD. Herein, we review the literature to analyze the association between the main genetic polymorphisms and the response to the existing therapeutic modalities. Patients with CFH high-risk alleles show a poorer response to preventive treatment of AMD with antioxidants and zinc.The association between genetic polymorphisms and response to photodynamic therapy and antiangiogenic drugs, however, is controversial until now.

Keywords: Macular degeneration/genetics;Antioxidants;Polymorphism, genetic;Treatment outcome

RESUMO

A degeneração macular relacionada à idade (DMRI) é uma doença degenerativa que afeta a retina central e envolve a membrana de Bruch, o epitélio pigmentar da retina e os fotorreceptores. Estudos recentes têm mostrado que polimorfismos dos genes CFH, LOC387715 e VEGF estão associados com a DMRI. Neste trabalho, é feita uma revisão da literatura para análise da associação entre os principais polimorfismos genéticos e a resposta às diferentes modalidades terapêuticas existentes. Observa-se que os pacientes portadores dos alelos de risco do gene CFH apresentam uma pior resposta ao tratamento preventivo da DMRI com antioxidantes e zinco. Já a associação entre o polimorfismo genético e a resposta à terapia fotodinâmica e às drogas antiangiogênicas é, até o momento, controversa.

Descritores: Degeneração macular/genética;Antioxidantes;Polimorfismo genético; Resultado de tratamento

INTRODUÇÃO

Age-related macular degeneration (AMD) is a degenerative disorder that affects the central retina and involves the Bruch's membrane, the retinal pigment epithelium (RPE) and the photoreceptors.^(1,2) It is characterized by a progressive, painless loss of central vision associated with ageing. AMD is considered the leading cause of irreversible blindness and responsible for a low quality of life in the affected population.^(1,3) In the United States of America population aged 40 years and older, the estimated prevalence of any AMD is 6.5%.⁽⁴⁾ The disease is usually classified into dry and wet types, responsible for 15% and 85% of cases, respectively. In the dry form, visual loss is usually gradual and is characterized by subretinal deposits called drusen or retinal pigment epithelial (RPE) abnormalities, including hyper or hypopigmentation. Larger drusen may become confluent and evolve into drusenoid RPE detachments, which can progress to geographic atrophy and less frequently to wet AMD. Wet AMD (also called exudative or neovascular AMD) occurs when choroidal neovascular membrane grows under the RPE or between the RPE and neurosensory retina, leading to subretinal hemorrhage and subsequent scar tissue formation.^(1,2)

Etiological research suggests that AMD is a complex disease, caused by the actions and interactions of multiple genes and environmental factors such as smoking and hypertension.^(5,6) Recent studies have shown that some genetic polymorphisms are associated with AMD. A genetic variation in the complement factor H (CFH) gene on chromosome 1q32 is one of the most studied gene polymorphisms related to AMD. This polymorphism (rs 1061170) results in a tyrosine-tohistidine substitution at amino acid position 402 (Y402H) in the CFH protein.^(7-33) The A69S polymorphism (rs 10490924) within the gene LOC387715 on chromosome 10q26 that leads to an alanine-to-serine substitution was also found to confer an increased risk for development of AMD.^(33-50) Some papers suggested that the vascular endothelial growth factor (VEGF) gene could play a role in the pathogenesis of AMD.^(51,58) However, many different single nucleotide polymorphisms (SNPs) were tested and limited sample sizes and diverse ethnic origin of cases and controls were studied to ensure a statistically valid conclusion. It has also been demonstrated that common CFH and LO387715 polymorphisms were independently related to progression from early or intermediate stages to advanced forms of the disease.⁽⁵⁹⁾ Herein, we review the main published studies that evaluate the response to the treatment of AMD related to genetic polymorphisms.

Klein et al. made a retrospective analysis of participants of a randomized, controlled clinical trial, the Age-Related Eye Disease Study (AREDS) to investigate the possible association between the response to oral antioxidants and zinc with genetic polymorphisms. The AREDS study enrolled 4757 participants from 11 clinical centers and established that a combination of zinc and antioxidants (B-carotene, vitamin C, and vitamin E) produced a 25% reduction in development of AMD over 5 years and a 19% reduction in severe vision loss in individuals determined to be at high risk of developing the advanced forms of the disease. A treatment interaction was observed between the CFH Y402H highrisk genotype and supplementation with antioxidants plus zinc (p = 0.03).An interaction (p = 0.004) was observed in the AREDS treatment groups taking zinc when compared with the groups taking no zinc, but not in groups taking antioxidants compared with those taking no antioxidants (p = 0.59). There were no significant treatment interactions observed with LOC387715.⁽⁶⁰⁾

Other authors have studied the effect of the LOC387715, CFH and VEGF genotypes on the response to photodynamic therapy (PDT) with controversial results.^(61,68) Goverdhan et al. genotyped a total of 557 cases with AMD and 551 normal controls for the CFH Y402H. Twenty-seven PDT-treated patients were followed up for 15 months and individuals with different CFH genotypes were then analyzed for any association with visual change following PDT.The number of patients carrying the high-risk C allele was 70.4% in those requiring PDT as compared to 52.3% in the non-PDT group (p=0.011), and presence of the CC genotype significantly increased the risk of PDT (p=0.015). The degree of visual loss following PDT was significantly higher in the CFH CC genotype group (p=0.038); 50% of CC cases and 45% of the CT cases lost 15 or more ETDRS letters at final follow-up. In conclusion, they showed that patients homozygous for the CFH high risk allele seem to have worse outcome after PDT.⁽⁶¹⁾ Brantley et al. also found a potential relationship between CFH genotype and response to PDT. However, they showed that patients with the CFH TT genotype (T: nonrisk allele) fared significantly worse with PDT than those with the CFH TC and CC genotypes.⁽⁶²⁾ Other studies did not show significant association between CFH polymorphism and PDT response for neovascular AMD.^(63,64) For LOC387715, two important studies have shown that there is no statistical significant difference among the genotypes in response to PDT.^(62,65) However, Sakurada et al. have recently shown that there is a pharmacogenetic association between the LOC387715 A69S variant and the long-term results after PDT in eyes with polypoidal choroidal vasculopathy (PCV). In this study, PDT was repeated every 3 months until the disappearance of angiographic signs of active lesions in 71 eyes of 71 patients with PCV who were followed-up for at least 12 months.There was a statistically significant difference in the visual acuity both at the 12-month and final visits (p = 0.002 and P < 0.001, respectively) with the poorer acuity in patients with the higher T-allele frequency.⁽⁶⁶⁾ Immonen et al. have evaluated VEGF gene polymorphism and the outcome after PDT and showed a strong relationship between this gene and the treatment results. The VEGF gene polymorphic SNPs at rs699947 and rs2146323 were strong determinants of the anatomic outcome after PDT, but the SNPs studied were not associated with the presence of exudative AMD or with the CNV lesion size or configuration.⁽⁶⁷⁾ However, Tsuchihashi et al. did not show any association between VEGF rs 699947 SNP and the response to PDT.⁽⁶⁸⁾ Other genetic polymorphisms and its relationship with the response to PDT were evaluated but showed no statistically significant results.^(62,67)

Recently, two studies have demonstrated the association between gene polymorphisms and the response to intravitreal injections of the antivascular endothelial growth factor (anti-VEGF) agents bevacizumab and ranibizumab.^(69,70) Brantley et al. conducted a study in which eighty-six patients with exudative AMD undergoing treatment with 1.25 mg intravitreal bevacizumab in one eye were enrolled. Intravitreal injections were performed at 6-week intervals until there was no longer evidence of active neovascularization. Each patient was followed for a minimum of 6 months. The authors showed that postbevacizumab VA was significantly worse in the CFH CC genotype than for the CFH TC or TT genotypes (p=0.016). However, there was no significant difference in response to this drug according to the LOC387715 genotypes.⁽⁶⁹⁾ The other pharmacogenetic study published three years later was conducted to determine whether CFH genotypes had an effect on the treatment of exudative AMD with ranibizumab. A total of 178 patients were studied and, for each patient, an intravitreal injection of 0.5 mg of ranibizumab was performed at the initial presentation of an active choroidal neovascular complex. Subsequent injections were performed as needed and patients were followed for a minimum of 9 months. In this retrospective study, Lee et al. found no difference in VA outcomes after ranibizumab treatment among the different CFH genotypes, in contrast to the previous study with bevacizumab. Nevertheless, over 9 months, patients with both risk alleles received approximately 1 more intravitreal injection.⁽⁷⁰⁾

There is only one study with a large number of patients that addresses the preventive treatment of dry AMD related to the genetic polymorphisms. As we can observe, the majority of published articles about the therapeutic response of exudative AMD are related the photodynamic therapy and many of them are controversial. Only two papers consider the intravitreal response to anti-VEGF agents according to the genetic polymorphisms. Since antiangiogenic therapy is now considered the gold standard treatment of exudative AMD, there is a long way to be traversed until treatment could be indicated according to the genetic profile of the patient. Additional studies with a larger number of patients, longer follow-up period and including more SNPs are important to establish a definite correlation between gene polymorphism and the therapeutic response in AMD. Only then may the treatment of this disease be recommended or modified based on genetic findings.

Recebido para publicação em 16/2/2011 - Aceito para publicação em 30/6/2011

Os autores declaram inexistir conflitos de interesse

• 1. Seddon JM, Chen CA. Epidemiology of age-related macular degeneration. In: Ryan SJ. Retina. 4th ed. Philadelphia: Elsevier; 2006.
• 2. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51(2):137-52. Comment in: Surv Ophthalmol. 2006;51(5):532; author reply 532.
• 3. Brown G, Brown MM. Let us wake the nation on the treatment for age-related macular degeneration. Curr Opin Ophthalmol. 2010;21(3):169-71.
• 4. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75-80.
• 5. Scholl HP, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BH. An update on the genetics of age-related macular degeneration. Mol Vis. 2007;13:196-205. Review.
• 6. Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Javier Nieto F, Huang GH, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128(6):750-8.
• 7. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and agerelated macular degeneration. Science. 2005;308(5720):421-4. Comment in: Science. 2005;308(5720):362-4.
• 8. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of agerelated macular degeneration. Science. 2005;308(5720):419-21. Comment in: Science. 2005;308(5720):362-4.
• 9. lein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-9. Comment in: Science. 2005;308(5720):362-4.
• 10. Zareparsi S, Branham KE, Li M, Shah S, Klein RJ, Ott J, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Human Genet. 2005;77(1):149-53.
• 11. Souied EH, Leveziel N, Richard F, Dragon-Durey MA, Coscas G, Soubrane G, et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis. 2005;11:1135-40.
• 12. Sepp T, Khan JC, Thurlby DA, Shahid H, Clayton DG, Moore AT, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006;47(2):536-40.
• 13. Postel EA,Agarwal A, Caldwell J, Gallins P,Toth C, Schmidt S, et al. Complement factor H increases risk for atrophic age-related macular degeneration. Ophthalmology. 2006;113(9):1504-7.
• 14. Schaumberg DA, Christen WG, Kozlowski P, Miller DT, Ridker PM, Zee RY. A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47(6):233640.
• 15. Simonelli F, Frisso G, Testa F, di Fiore R, Vitale DF, Manitto MP, et al. Polymorphism p.402Y>H in the complement factor H protein is a risk factor for age related macular degeneration in an Italian population. Br J Ophthalmol. 2006;90(9):1142-5. Comment in: Br J Ophthalmol. 2006;90(9):1080-1.
• 16. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296(3):301-9.
• 17. Seitsonen S, Lemmelä S, Holopainen J, Tommila P, Ranta P, Kotamies A, et al. Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Mol Vis. 2006;12:796-801.
• 18. Lau LI, Chen SJ, Cheng CY, Yen MY, Lee FL, Lin MW, et al. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci. 2006;47(8):3242-6.
• 19. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol. 2007;125(1):55-62. Comment in: JAMA. 2007;297(4):401-2.
• 20. Scott WK, Schmidt S, Hauser MA, Gallins P, Schnetz-Boutaud N, Spencer KL, et al. Independent effects of complement factor H Y402H polymorphism and cigarette smoking on risk of age-related macular degeneration. Ophthalmology. 2007;114(6):1151-6.
• 21. Wegscheider BJ, Weger M, Renner W, Steinbrugger I, März W, Mossböck G, et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology. 2007;114(4):738-42.
• 22. Brantley MA Jr, Edelstein SL, King JM, Apte RS, Kymes SM, Shiels A. Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. Am J Ophthalmol. 2007;144(3):404-8.
• 23. Ricci F, Zampatti S, D'Abbruzzi F, Missiroli F, Martone C, Lepre T, et al. Typing of ARMS2 and CFH in age-related macular degeneration: case-control study and assessment of frequency in the Italian population. Arch Ophthalmol. 2009;127(10):1368-72.
• 24. Gotoh N, Yamada R, Nakanishi H, Saito M, Iida T, Matsuda F, Yoshimura N. Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population. Clin Experiment Ophthalmol. 2008;36(5):437-42.
• 25. Chowers I, Cohen Y, Goldenberg-Cohen N, Vicuna-Kojchen J, Lichtinger A, Weinstein O, et al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol Vis. 2008;14:1829-34.
• 26. Kim IK, Ji F, Morrison MA, Adams S, Zhang Q, Lane AM, et al. Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration. Mol Vis. 2008;14:1487-95.
• 27. Xu Y, Guan N, Xu J, Yang X, Ma K, Zhou H, et al. Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population. Mol Vis. 2008;14:1373-81.
• 28. Teixeira AG, Silva AS, Lin FL, Velletri R, Bavia L, Belfort R, Isaac L. Association of complement factor H Y402H polymorphism and age-related macular degeneration in Brazilian patients. Acta Ophthalmol. 2010;88(5):e165-9.
• 29. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH. C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology. 2010;117(10):1982-8.
• 30. Hayashi H, Yamashiro K, Gotoh N, Nakanishi H, Nakata I, Tsujikawa A, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2010;51(11):5914-9.
• 31. Yang X, Hu J, Zhang J, Guan H. Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese. Br J Ophthalmol. 2010;94(9):1211-4.
• 32. Liu X, Zhao P, Tang S, Lu F, Hu J, Lei C, et al. Association study of complement factor H, C2, CFB, and C3 and agerelated macular degeneration in a Han Chinese population. Retina. 2010;30(8):1177-84.
• 33. Shuler RK Jr, Hauser MA, Caldwell J, Gallins P, Schmidt S, Scott WK, et al. Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism. Arch Ophthalmol. 2007;125(1):63-7.
• 34. Jakobsdottir J,Conley YP, Weeks DE,Mah TS,Ferrell RE,Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005;77(3):389-407.
• 35. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical LOC387715 is a second major susceptibility gene for age related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14(21):3227-36.
• 36. Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 2006;78(5):852-64.
• 37. Fisher SA, Rivera A, Fritsche LG, Babadjanova G, Petrov S, Weber BH. Assessment of the contribution of CFH and chromosome 10q26 AMD susceptibility loci in a Russian population isolate. Br J Ophthalmol. 2007;91(5):576-8.
• 38. Tanimoto S, Tamura H, Ue T, Yamane K, Maruyama H, Kawakami H, Kiuchi Y. A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population. Neurosci Lett. 2007;414(1):71-4.
• 39. Ross RJ, Bojanowski CM, Wang JJ, Chew EY, Rochtchina E, Ferris FL 3rd, et al. The LOC387715 polymorphism and agerelated macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci. 2007;48(3):1128-32.
• 40. Francis PJ, George S, Schultz DW, Rosner B, Hamon S, Ott J, et al. The LOC387715 gene, smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered. 2007;63(3-4):212-8.
• 41. Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2007;104(41):16227-32. Comment in: Proc Natl Acad Sci U S A. 2007;104(43):16725-6.
• 42. Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN, Weber BH. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008;40(7):892-6. Comment in: Nat Genet. 2008;40(7):820-1.
• 43. Francis PJ, Zhang H, Dewan A, Hoh J, Klein ML. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis. 2008;14:1395-400.
• 44. Neuner B, Wellmann J, Dasch B, Dietzel M, Farwick A, Stoll M, et al. LOC387715, smoking and their prognostic impact on visual functional status in age-related macular degeneration-The Muenster Aging and Retina Study (MARS) cohort. Ophthalmic Epidemiol. 2008;15(3):148-54.
• 45. Shuler RK Jr, Schmidt S, Gallins P, Hauser MA, Scott WK, Caldwell J, et al. Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration. Am J Ophthalmol. 2008;145(2):303-7.
• 46. Andreoli MT, Morrison MA, Kim BJ, Chen L, Adams SM, Miller JW, et al. Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. Am J Ophthalmol. 2009;148(6):869-74.
• 47. Jiang H, Qu Y, Dang G, Zhang X, Yin N, Zhang Y, et al. Analyses of single nucleotide polymorphisms and haplotype linkage of LOC387715 and the HTRA1 gene in exudative age-related macular degeneration in a Chinese cohort. Retina. 2009;29(7):974-9.
• 48. Gotoh N, Nakanishi H, Hayashi H, Yamada R, Otani A, Tsujikawa A, et al. ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;147(6):1037-41,1041.e1-2.
• 49. Tong Y, Liao J, Zhang Y, Zhou J, Zhang H, Mao M. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis. Mol Vis. 2010;16:1958-81.
• 50. Lee SJ, Kim NR, Chin HS. LOC387715/HTRA1 polymorphisms, smoking and combined effects on exudative age-related macular degeneration in a Korean population. Clin Experiment Ophthalmol. 2010;38(7):698-704.
• 51. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK,Agarwal A, Postel EA, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF,VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47(1):329-35.
• 52. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet. 2006;15(19):2955-61.
• 53. Richardson AJ, Islam FM, Guymer RH, Cain M, Baird PN. A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis. 2007;13:2148-52.
• 54. Boekhoorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, Vingerling JR. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology. 2008;115(11):1899-903.
• 55. Lin JM, Wan L, Tsai YY, Lin HJ, Tsai Y, Lee CC, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol. 2008;145(6):1045-51.
• 56. Janik-Papis K, Zaras M, Krzyzanowska A, Wozniak K, Blasiak J, Szaflik J, Szaflik JP. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol. 2009;87(3):234-8.
• 57. Fang AM, Lee AY, Kulkarni M, Osborn MP, Brantley MA Jr. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis. 2009;15:2710-9.
• 58. Galan A, Ferlin A, Caretti L, Buson G, Sato G, Frigo AC, Foresta C. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology. 2010;117(9):1769-74.
• 59. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007;297(16):1793-800. Erratum in: JAMA. 2007;297(23):2585. Comment in: JAMA. 2007;298(14):1637; author reply 1637.
• 60. Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology. 2008;115(6):1019-25.
• 61. Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, Lotery AJ. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond). 2008;22(6):849-54.
• 62. Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative agerelated macular degeneration to photodynamic therapy. Eye (Lond). 2009;23(3):626-31.
• 63. Feng X, Xiao J, Longville B, Tan AX, Wu XN, Cooper MN, et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology. 2009;116(10):190812.e1.
• 64. Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, Immonen IJ. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in agerelated macular degeneration. Eur J Ophthalmol. 2007;17(6):943-9.
• 65. Chowers I, Meir T, Lederman M, Goldenberg-Cohen N, Cohen Y, Banin E, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis. 2008;14:2263-71.
• 66. Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2010;30(10):1616-21.
• 67. Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER, et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2010;117(1):103-8.
• 68. Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, Takita H, et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology. 2011;118(1):93-100.
• 69. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114(12):2168-73.
• 70. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93(5):610-3.

Endereço para correspondência:

Carlos Eduardo dos Reis Veloso

Rua dos Otoni, nº 881 - 13º andar – Santa Efigênia

CEP 30150-270 – Belo Horizonte – (MG), Brasil

Publication Dates

• Publication in this collection
  31 July 2012
• Date of issue
  June 2012

History

• Received
  16 Feb 2011
• Accepted
  30 June 2011